PolyPid receives Nasdaqs non-compliance letter
PYPD Stock | USD 2.79 0.08 2.79% |
About 61% of PolyPid's investor base is looking to short. The analysis of the overall investor sentiment regarding PolyPid suggests that many traders are alarmed. The current market sentiment, together with PolyPid's historical and current headlines, can help investors time the market. In addition, many technical investors use PolyPid stock news signals to limit their universe of possible portfolio assets.
PolyPid |
PolyPid faces Nasdaq delisting for failing to meet minimum stockholders equity requirement. Company has until Jan.
Read at seekingalpha.com
PolyPid Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards PolyPid can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
PolyPid Fundamental Analysis
We analyze PolyPid's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PolyPid using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PolyPid based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
PolyPid is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
PolyPid Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with PolyPid stock to make a market-neutral strategy. Peer analysis of PolyPid could also be used in its relative valuation, which is a method of valuing PolyPid by comparing valuation metrics with similar companies.
Peers
PolyPid Related Equities
ELEV | Elevation Oncology | 15.38 | ||||
CUE | Cue Biopharma | 3.64 | ||||
CYTO | Altamira Therapeutics | 2.17 | ||||
ZURA | Zura Bio | 0.72 | ||||
ANEB | Anebulo Pharmaceuticals | 0.64 | ||||
ARMP | Armata Pharmaceuticals | 0.45 | ||||
ANIX | Anixa Biosciences | 2.00 | ||||
VRPX | Virpax Pharmaceuticals | 3.13 | ||||
INMB | INmune Bio | 3.49 | ||||
KPRX | Kiora Pharmaceuticals | 3.57 | ||||
PYXS | Pyxis Oncology | 5.62 | ||||
VRAX | Virax Biolabs | 6.08 | ||||
REVB | Revelation Biosciences | 6.67 | ||||
INAB | In8bio | 8.82 |
Complementary Tools for PolyPid Stock analysis
When running PolyPid's price analysis, check to measure PolyPid's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PolyPid is operating at the current time. Most of PolyPid's value examination focuses on studying past and present price action to predict the probability of PolyPid's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PolyPid's price. Additionally, you may evaluate how the addition of PolyPid to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |